Table 1:
Participant characteristics for the overall sample and fatigue severity subgroups
| Variable | Overall Sample (N=218) |
Non-Fatigued (n=72) |
Fatigued (n=146) |
p-value |
|---|---|---|---|---|
| Age (years) | 59.3 ± 10.1 | 60.5 ± 9.1 | 58.7 ± 10.6 | 0.297* |
| Gender (n (%) Female) | 179 (82%) | 58 (81%) | 121 (83%) | 0.674 |
| Race (n (%)) | 0.458 | |||
| Caucasian | 209 (96%) | 69 (96%) | 140 (96%) | — |
| Latino/Latina | 4 (2%) | 1 (1%) | 3 (2%) | — |
| Black/African American | 2 (1%) | 0 (0%) | 2 (1%) | — |
| Employed (n (%)) | 84 (39%) | 34 (47%) | 50 (35%) | 0.082 |
| MS Type (n (%)) | 0.339 | |||
| Relapsing-remitting MS | 153 (70%) | 53 (74%) | 100 (69%) | — |
| Secondary Progressive MS | 38 (17%) | 12 (17%) | 26 (18%) | — |
| Primary Progressive MS | 24 (11%) | 5 (7%) | 19 (13%) | — |
| MS Disease Duration (years) | 19.9 ± 9.3 | 20.4 ± 8.5 | 19.7 ± 9.7 | 0.515* |
| PDDS (median [IQR]) | 3 [4.0] | 1.0 [3.0] | 3.0 [4.0] | <0.001 |
| DMT Use (n (%)) | 184 (84%) | 60 (83%) | 124 (85%) | 0.935 |
| FSS Score | 4.6 ± 1.7 | 2.5 ± 0.9 | 5.6 ± 0.8 | <0.001* |
Notes: Values are presented as mean ± standard deviation unless otherwise specified; Non-fatigued based on an FSS score of < 4; Fatigued based on an FSS score ≥ 4; *] Mann-Whitney U test; MS Multiple Sclerosis; PDDS Patient Determined Disease Status; DMT Disease-modifying Therapy; FSS Fatigue Severity Scale.